German biotech firm Morphosys said this week its diagnostic antibody unit AbD Serotec has amended its existing license agreement with Merck to include use of its HuCAL Gold technology for vaccine research.
The agreement grants Merck access to the company's HuCAL Gold antibody library for research purposes, as well as the option to upgrade to Morphosys's HuCAL Platinum library.
AbD Serotec will receive annual user fees from Merck for access to the HuCAL technology and license fees for clinical monitoring reagents.